DRMA

Dermata Therapeutics Inc

NASDAQ: DRMA · HEALTHCARE · BIOTECHNOLOGY

$1.46

-9.32% today

Updated 2026-08-27

Market cap

$5.91M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-4.32

Dividend yield

—

52W range

$1 – $6

Volume

0.9M

Market cap

$5.91M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-4.32

Dividend yield

—

52W range

$1 – $6

Volume

0.9M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

5.5

Quality

C+

3.0

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →248 stocks currently score above 75

Price targets

Analyst target

$4.00

+173.97%

12-Month target

$1.37

-6.16%

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy0 Buy0 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

Insufficient data

Risks

- Piotroski 3/9 — weak financial health

- Thin margins at 0.00%

- Negative free cash flow $-2.53M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	—
Net income	$-9.61M	$-7.79M	$-12.29M	$-7.56M	$-2.97M
EPS	—	—	—	—	$-4.32
Free cash flow	$-8.83M	$-6.41M	$-11.16M	$-7.76B	$-2.53M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
DRMA	$5.91M	23	4.3	3.0	5.0	5.5	—	Avoid
LLY	$1.06T	76	9.3	10.0	5.0	6.0	—	Strong Buy
JNJ	$632.29B	57	4.7	8.5	3.7	6.0	—	Buy
ABBV	$442.36B	73	6.7	8.5	4.7	5.0	-74.90%	Strong Buy
UNH	$355.11B	62	7.3	5.5	4.7	6.0	-22.14%	Buy
MRK	$335.46B	34	4.0	4.5	2.0	5.0	-84.64%	Avoid

Smart narrative

Dermata Therapeutics Inc trades at $1.46. Our Smart Value Score of 23/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score.

Frequently asked questions

What is Dermata Therapeutics Inc's stock price?

Dermata Therapeutics Inc (DRMA) trades at $1.46.

Is Dermata Therapeutics Inc overvalued?

Dermata Therapeutics Inc carries a Smart Value Score of 23/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Dermata Therapeutics Inc (DRMA)?

The 12-month analyst consensus target is $4.00, about 174.0% above the current $1.46. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-110.75%

Beta0.66

50D MA$1.27

200D MA$1.70

Shares out0.00B

Float0.00B

Short ratio—

Avg volume0.9M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

DRMA vs LLY →DRMA vs JNJ →DRMA vs ABBV →Stock screener →